Antidepressant Linked to Liver Failure Pulled From Market

The maker of Serzone (generically called nefazodone) will pull the controversial antidepressant off the U.S. market next month, blaming a decline in sales rather than concern about a risk of liver failure. Serzone was already pulled off the market in many other countries, and maker Bristol-Myers Squibb is under mounting pressure from lawsuits. The FDA has received reports of at least 55 cases of liver failure, including 20 deaths, and another 39 cases of less severe liver injury since Serzone began selling in 1994. This is the same antidepressant that the FDA was sued over last year.

USA Today April 19, 2004

Post your comment
Click Here and be the first to comment on this article